Transcriptional Expression Analysis of Survivin Splice Variants Reveals Differential Expression of Survivin-3 alpha in Breast Cancer

Abstract

Survivin, which is a novel member of the inhibitor of apoptosis family proteins, is known to play an important role in the regulation of cell cycle and apoptosis. Differential expression of survivin in tumor tissues introduces it as a new candidate molecular marker for cancer. Here we investigated the expression of survivin and its splice variants in breast tumors, as well as normal adjacent tissues obtained from the same patients. Thirty five tumors and 17 normal adjacent tissues from women diagnosed with breast cancer were explored in this study. Differential expression of different survivin splice variants was detected and semiquantitatively analyzed using reverse transcription-polymerase chain reaction. Results showed that survivin and its splice variants were differentially expressed in tumor specimens compared with normal adjacent tissues. The expression of survivin-3B and survivin-3 alpha was specifically detected in tumor tissues compared with normal adjacent ones (53% in tumor tissues compared to 5% in normal adjacent for survivin-3B and 65% in tumor tissues and 0.0% in normal adjacent tissues for survivin-3 alpha). Statistical analysis showed that survivin and survivin-Delta Ex3 were upregulated in benign (90%, p < 0.034) and malignant (76%, p < 0.042) tumors, respectively. On the other hand, our results showed that survivin-2 alpha (100% of the cases) was the dominant expressed variant of survivin in breast cancer. The data presented here showed that survivin splice variants were differentially expressed in benign and malignant breast cancer tissues, suggesting their potential role in breast cancer development. Differential expression of survivin-2 alpha and survivin-3 alpha splice variants highlights their usefulness as new candidate markers for breast cancer diagnosis and prognosis.